When BC Partners invested in Synthon, a leading developer and manufacturer of complex generics, the opportunity was clear: build on a strong foundation and accelerate growth.
Working closely with management, BC Partners focused on investing heavily in R&D to expand the pipeline, driving operational excellence and accelerating geographic and commercial expansion. The result was a transformation that delivered strong top- and bottom-line growth and positioned the business for its next chapter.
In 2024, Synthon was sold to Goldman Sachs Alternatives following one of the most competitive private equity exit processes of the year. The investment was later recognised as Benelux Deal of the Year at the 2026 Real Deals Private Equity Awards.
Watch below to hear from Synthon CEO Anish Mehta on the company’s transformation journey, the partnership with BC Partners, and the key drivers behind its growth and successful exit.
